Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 1 Deaths at end of follow up (FU).
Figuras y tablas -
Analysis 1.1

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 1 Deaths at end of follow up (FU).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 2 Participants requiring add‐on therapy.
Figuras y tablas -
Analysis 1.2

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 2 Participants requiring add‐on therapy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 3 Development of motor fluctuations.
Figuras y tablas -
Analysis 1.3

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 3 Development of motor fluctuations.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 4 Development of dyskinesias.
Figuras y tablas -
Analysis 1.4

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 4 Development of dyskinesias.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 5 Total withdrawals.
Figuras y tablas -
Analysis 1.5

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 5 Total withdrawals.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 6 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 1.6

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 6 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 7 Withdrawals due to nausea.
Figuras y tablas -
Analysis 1.7

Comparison 1 Monoamine oxidase B inhibitors versus levodopa, Outcome 7 Withdrawals due to nausea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 1 Deaths at end of follow up (FU).
Figuras y tablas -
Analysis 2.1

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 1 Deaths at end of follow up (FU).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 2 Participants requiring add‐on therapy.
Figuras y tablas -
Analysis 2.2

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 2 Participants requiring add‐on therapy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 3 Development of motor fluctuations.
Figuras y tablas -
Analysis 2.3

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 3 Development of motor fluctuations.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 4 Development of dyskinesias.
Figuras y tablas -
Analysis 2.4

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 4 Development of dyskinesias.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 5 Total withdrawals.
Figuras y tablas -
Analysis 2.5

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 5 Total withdrawals.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 6 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 2.6

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 6 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 7 Withdrawals due to nausea.
Figuras y tablas -
Analysis 2.7

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 7 Withdrawals due to nausea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 8 Subjects with adverse events.
Figuras y tablas -
Analysis 2.8

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 8 Subjects with adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 9 Nausea.
Figuras y tablas -
Analysis 2.9

Comparison 2 Monoamine oxidase inhibitors versus dopamine agonists, Outcome 9 Nausea.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Monoamine oxidase B inhibitors versus levodopa

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Deaths at end of follow up (FU) Show forest plot

1

303

Odds Ratio (M‐H, Random, 95% CI)

0.96 [0.52, 1.76]

2 Participants requiring add‐on therapy Show forest plot

1

311

Odds Ratio (M‐H, Random, 95% CI)

12.02 [6.78, 21.31]

3 Development of motor fluctuations Show forest plot

1

311

Odds Ratio (M‐H, Random, 95% CI)

0.55 [0.32, 0.94]

4 Development of dyskinesias Show forest plot

1

311

Odds Ratio (M‐H, Random, 95% CI)

0.71 [0.42, 1.19]

5 Total withdrawals Show forest plot

1

332

Odds Ratio (M‐H, Random, 95% CI)

2.39 [1.33, 4.30]

6 Withdrawals due to adverse events Show forest plot

1

332

Odds Ratio (M‐H, Random, 95% CI)

0.49 [0.09, 2.73]

7 Withdrawals due to nausea Show forest plot

1

332

Odds Ratio (M‐H, Random, 95% CI)

0.20 [0.01, 4.15]
Figuras y tablas -
Comparison 1. Monoamine oxidase B inhibitors versus levodopa
Ir a la tabla de la revisión
Comparison 2. Monoamine oxidase inhibitors versus dopamine agonists

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Deaths at end of follow up (FU) Show forest plot

2

400

Odds Ratio (M‐H, Random, 95% CI)

1.30 [0.69, 2.45]

2 Participants requiring add‐on therapy Show forest plot

2

409

Odds Ratio (M‐H, Random, 95% CI)

2.00 [1.05, 3.81]

3 Development of motor fluctuations Show forest plot

1

317

Odds Ratio (M‐H, Random, 95% CI)

1.15 [0.65, 2.05]

4 Development of dyskinesias Show forest plot

1

317

Odds Ratio (M‐H, Random, 95% CI)

1.50 [0.84, 2.68]

5 Total withdrawals Show forest plot

2

427

Odds Ratio (M‐H, Random, 95% CI)

0.60 [0.39, 0.91]

6 Withdrawals due to adverse events Show forest plot

2

427

Odds Ratio (M‐H, Random, 95% CI)

0.11 [0.01, 0.99]

7 Withdrawals due to nausea Show forest plot

1

335

Odds Ratio (M‐H, Random, 95% CI)

0.02 [0.00, 0.26]

8 Subjects with adverse events Show forest plot

1

92

Odds Ratio (M‐H, Random, 95% CI)

0.65 [0.21, 2.00]

9 Nausea Show forest plot

1

92

Odds Ratio (M‐H, Random, 95% CI)

1.14 [0.35, 3.69]
Figuras y tablas -
Comparison 2. Monoamine oxidase inhibitors versus dopamine agonists
Ir a la tabla de la revisión